gabapentin and Obsessive-Compulsive Disorder

gabapentin has been researched along with Obsessive-Compulsive Disorder in 7 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.

Research

Studies (7)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Anxiety Symptoms as Measured by the Generalized Anxiety Disorder-7 (GAD-7) Scale

GAD-7 is GAD-7 is a 7-item self-administered scale of Generalized Anxiety Disorder symptoms (0 = not at all to 3 = nearly every day). Total scores range from 0 to 21. Total scores of 0-4 = minimal anxiety, Total scores of 5-9 = mild anxiety, total scores of 10-14 = moderate anxiety and total scores of 15-21 = severe anxiety. (NCT03012815)
Timeframe: Baseline and 2 days

Change in Cravings as Assessed by the Penn Alcohol Craving (PACS) Scale

PACS is a 5 item self-rated scale of alcohol craving (0 = none to 6 = strong urge). Total scores range from 0 (little craving for alcohol) to 30 (irresistible urge to drink alcohol) (NCT03012815)
Timeframe: Baseline and 2 days

Change in Sleepiness as Assessed by the Epworth Sleepiness Scale

The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their daytime sleepiness. (NCT03012815)
Timeframe: Baseline and 2 days

Maximun Alcohol Withdrawal Severity Per CIWA-Ar Scale

CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: 4 days

Mean Length of Hospital Stay

The length of hospital stay for Alcohol withdrawal syndrome. The time interval between admission and either discharge or the time at which Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar) scores are <10 for 36 hours (up to 240 hours). Measured in hours. CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.

Mean Total Benzodiazepine Use

The total amount of benzodiazepines administered. Measured by lorazepam equivalent, mg. (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.

Number of Participants Experiencing Seizure

The number of subjects who developed seizure during their hospitalization. (NCT03012815)
Timeframe: During hospitalization (up to 240 hours).

Number of Participants With Delirium Tremens (DT)

The number of participants experiencing delirium tremens during their hospitalization (between admission and discharge). (NCT03012815)
Timeframe: During hospitalization (up to 240 hours)

Trials

4 trials available for gabapentin and Obsessive-Compulsive Disorder

Other Studies

3 other studies available for gabapentin and Obsessive-Compulsive Disorder